Lung Cancer

Mirdametinib NDA gets priority review in NF1-associated plexiform neurofibromas, experts explore social media's evolving role in cancer care, and more.

Encorafenib plus binimetinib has won approval from the European Commission for use in patients with BRAF V600E-mutated, advanced non–small lung cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

Krishnansu S. Tewari, MD, details the current and possible future applications of AI in cancer care as well as the limitations of the technology.

Amivantamab plus chemotherapy has received European approval for EGFR-mutant non–small cell lung cancer that progressed on an EGFR TKI.

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

Data from the INSIGHT 2 study showed that tepotinib plus osimertinib elicited responses in patients with EGFR-mutated non–small cell lung cancer.

China’s National Medical Products Administration has approved fulzerasib for the treatment of adult patients with advanced KRAS G12C–mutant NSCLC.

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail new trial design proposals for perioperative regimens in resectable NSCLC.

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, discuss data with perioperative durvalumab in resectable NSCLC in light of the ODAC decision.

GSK5764227 has received breakthrough therapy designation from the FDA for use in select patients with extensive-stage small cell lung cancer.

An NDA seeking approval of sacituzumab tirumotecan for select patients with EGFR+ non–small cell lung cancer has been accepted by the NMPA's CDE.

The FDA has approved first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

The FDA has granted orphan drug designation to PT217 for the treatment of patients with neuroendocrine carcinoma.

The FDA has lifted a partial clinical hold on the phase 1 trial evaluating YL202 in advanced breast cancer and EGFR-mutated non–small cell lung cancer.

The FDA has approved neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, for select resectable non–small cell lung cancer.

Head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Ivonescimab has been granted priority review in China for the frontline treatment of patients with PD-L1–positive locally advanced or metastatic NSCLC.

The FDA granted priority review to durvalumab in limited-stage small cell lung cancer after platinum-based concurrent chemoradiotherapy.

The FDA has granted fast track designation to Deltacel in combination with low-dose radiation for pretreated metastatic non–small cell lung cancer.

Clinicians specializing in caring for patients with lung cancer discussed clinical trial updates on agents in stage III NSCLC.

Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.

Benjamin Levy, MD, compares the common toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd), and shares practical tips for managing these toxicities in the clinical setting to optimize patient care and minimize adverse effects.

Julia Rotow, MD, highlights and discusses other notable antibody-drug conjugate (ADC) data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, providing insights into the potential impact of these findings on the evolving treatment landscape for non-small cell lung cancer (NSCLC).

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

Charu Aggarwal, MD, MPH, FASCO, discusses the evaluation of CAN-2409, valacyclovir, and continued immune checkpoint inhibitors in NSCLC.

Deltacel generated early signals of clinical efficacy in patients with metastatic non–small cell lung cancer who have not responded to standard therapies.

Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.

The KeyVibe-008 trial evaluating vibostolimab, pembrolizumab, and chemotherapy in extensive-stage small cell lung cancer has been discontinued.